Your browser doesn't support javascript.
loading
Cross-cultural adaptation of the Spanish MINICHAL instrument into English for use in the United Kingdom.
Jordan, Andrew N; Anning, Christine; Wilkes, Lindsay; Ball, Claire; Pamphilon, Nicola; Clark, Christopher E; Bellenger, Nicholas G; Shore, Angela C; Sharp, Andrew S P; Valderas, Jose M.
Afiliação
  • Jordan AN; NIHR Exeter Clinical Research Facility, Vascular Medicine, University Hospitals Dorset, Exeter, UK. andrew.jordan@uhd.nhs.uk.
  • Anning C; Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, EX2 5AX, UK. andrew.jordan@uhd.nhs.uk.
  • Wilkes L; NIHR Exeter Clinical Research Facility, Vascular Medicine, University Hospitals Dorset, Exeter, UK.
  • Ball C; NIHR Exeter Clinical Research Facility, Vascular Medicine, University Hospitals Dorset, Exeter, UK.
  • Pamphilon N; NIHR Exeter Clinical Research Facility, Vascular Medicine, University Hospitals Dorset, Exeter, UK.
  • Clark CE; NIHR Exeter Clinical Research Facility, Vascular Medicine, University Hospitals Dorset, Exeter, UK.
  • Bellenger NG; Health Services and Policy Research Group, Exeter Collaboration for Academic Primary Care (APEx), NIHR School for Primary Care Research, University of Exeter, Smeall Building, St Luke's Campus, Magdalen Road, Exeter, EX1 2LU, UK.
  • Shore AC; Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, EX2 5AX, UK.
  • Sharp ASP; Department of Cardiology, Royal Devon and Exeter Hospital, Exeter, UK.
  • Valderas JM; NIHR Exeter Clinical Research Facility, Vascular Medicine, University Hospitals Dorset, Exeter, UK.
Health Qual Life Outcomes ; 20(1): 39, 2022 Mar 04.
Article em En | MEDLINE | ID: mdl-35246164
ABSTRACT

BACKGROUND:

Hypertension is a highly prevalent condition, with optimal treatment to BP targets conferring significant gains in terms of cardiovascular outcomes. Understanding why some patients do not achieve BP targets would be enhanced through greater understanding of their health-related quality of life (HRQoL). However, the only English language disease-specific instruments for measurement of HRQoL in hypertension have not been validated in accordance with accepted standards. It is proposed that the Spanish MINICHAL instrument for the assessment of HRQoL in hypertension could be translated, adapted and validated for use in the United Kingdom. The aim of the study was therefore to complete this process.

METHODS:

The MINICHAL authors were contacted and the original instrument obtained. This was then translated into English by two independent English-speakers, with these versions then reconciled, before back-translation and subsequent production of a 2nd reconciled version. Thereafter, a final version was produced after cognitive debriefing, for administration and psychometric analysis in the target population of patients living in the Exeter area (Southwest UK) aged 18-80 years with treatment-naïve grade II-III hypertension, before, during and after 18 weeks' intensive treatment.

RESULTS:

The English-language instrument was administered to 30 individuals (median age 58.5 years, 53% male). Psychometric analysis demonstrated a floor effect, though no ceiling effect. Internal consistency for both state of mind (StM) and somatic manifestations (SM) dimensions of the instrument were acceptable (Cronbach's alpha = 0.81 and 0.75), as was test-retest reliability (ICC = 0.717 and 0.961) and construct validity, which was measured through co-administration with the EQ-5D-5L and Bulpitt-Fletcher instruments. No significant associations were found between scores and patient characteristics known to affect HRQoL. The EQ-5D-5L instrument found an improvement in HRQoL following treatment, with the StM and SM dimensions of the English language MINICHAL trending to support this (d = 0.32 and 0.02 respectively).

CONCLUSIONS:

The present study details the successful English translation and validation of the MINICHAL instrument for use in individuals with hypertension. The data reported also supports an improvement in HRQoL with rapid treatment of grade II-III hypertension, a strategy which has been recommended by contemporaneous European guidelines. Trial registration ISRCTN registry number 57475376 (assigned 25/06/2015).
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Idioma Tipo de estudo: Guideline / Qualitative_research Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Idioma Tipo de estudo: Guideline / Qualitative_research Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article